Evidence map›Paper›PMID 40636348›Full record

ReviewiLIVER2022

Precise cell therapy for liver fibrosis: Endothelial cell and macrophage therapy.

Liping Deng, Bingjie Wu, Kaini Liang, Hongen Liao, Yanan Du

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in iLIVER, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Liping DengDepartment of Biomedical Engineering, School of Medicine, Tsinghua University, Beijing, 10084, China.
Bingjie WuDepartment of Biomedical Engineering, School of Medicine, Tsinghua University, Beijing, 10084, China.
Kaini LiangDepartment of Biomedical Engineering, School of Medicine, Tsinghua University, Beijing, 10084, China.
Hongen LiaoDepartment of Biomedical Engineering, School of Medicine, Tsinghua University, Beijing, 10084, China.
Yanan DuDepartment of Biomedical Engineering, School of Medicine, Tsinghua University, Beijing, 10084, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liver fibrosis is typically caused by chronic viral hepatitis and, more recently, fatty liver disease associated with obesity. There are currently no approved drugs for liver cirrhosis, and liver transplantation is limited by donor scarcity, thus driving the investigation of novel therapeutic strategies. The development of liver fibrosis presents with stage- and zone-dependent characteristics that manifest as distinct dynamic changes during vascularization and extracellular matrix (ECM) deposition. However, current cellular therapies do not consider the spatiotemporal variations of liver fibrosis without identifying the precise location and stage to administer the intervention to achieve optimal therapeutic effects. Herein, we focus on endothelial cell (EC) and macrophage therapy for liver fibrosis because of their important roles in regulating the spatiotemporal changes of vascularization and ECM deposition during liver fibrosis progression. Overall, this review summarizes the stage-dependent EC and macrophage therapy for liver fibrosis, elucidates their respective mechanisms, and exemplifies potential strategies to realize precise cell therapy by targeting specific liver zones.

Indexed as

Endothelial cellExtracellular matrix depositionLiver fibrosisMacrophagePrecise cell therapyVascularization

Identifiers

PMID40636348
PMCPMC12212654

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.